Kodiak Sciences is trading at $89.42, down 5.3%, with no clear October 5 company-specific catalyst in available reports.

  • LifeSci Capital raised its target to $145 from $85 and maintained an Outperform rating; this does not explain the drop.
  • A sharp rally followed September 28 Phase 3 DAYBREAK results, which showed Zenkuda and tabirafusp-ted met wet AMD primary endpoints; this is not a confirmed cause today.
  • Broader indices are mixed; none is down more than 0.5% in the same direction.